1)日本臨床衛生検査技師会(監).JAMT検査技術教本シリーズ 一般検査技術教本.丸善出版,2012.
2)横山貴,他.一般性状検査から白血球分類検査まで.Med Technol.2017;45:405-410.
3)腹膜透析ガイドライン改訂ワーキンググループ(編).腹膜透析ガイドライン2019.医学図書出版,2019.
4)Twardowski ZJ, et al. Peritoneal equilibration test. Perit Dial Bull. 1987; 7: 138-147.
5)出居真由美,他.腹膜透析患者における腹膜劣化の指標.日臨検医会誌.2021;69:487-492.
6)出居真由美,三井田孝.腹膜透析における腹膜劣化の評価方法—新規腹膜劣化指標としてERC/mesothelinの有用性.臨化.2023;52:186-192.
7)Ho-dac-Pannekeet MM, et al. Longitudinal follow-up of CA125 in peritoneal effluent. Kidney Int. 1997; 51: 888-893.
8)Sampimon DE, et al. Early diagnostic markers for encapsulating peritoneal sclerosis: a case-control study. Perit Dial Int. 2010; 30: 163-169.
9)Pecoits-Filho R, et al. Plasma and dialysate IL-6 and VEGF concentrations are associated with high peritoneal solute transport rate. Nephrol Dial Transplant. 2002; 17: 1480-1486.
10)Hirahara I, et al. The potential of matrix metalloproteinase-2 as a marker of peritoneal injury, increased solute transport, or progression to encapsulating peritoneal sclerosis during peritoneal dialysis--a multicentre study in Japan. Nephrol Dial Transplant. 2007; 22: 560-567.